Cited by 205Receptor Mechanisms and SignalingNeurotransmitter Receptor Influence on BehaviorSchizophrenia research and treatment

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1-adrenergic receptors in vitro

Bymaster, F·1999·Schizophrenia Research

DOI 10.1016/s0920-9964(98)00146-7

Open this paper in CoChat — free account

Abstract

The atypical antipsychotic olanzapine has relatively high affinity for a number of neuronal receptors in radioreceptor binding assays. The ability of olanzapine to activate or antagonize a number of neuronal receptors was investigated in vitro, in cell lines transfected selectively with receptor subtypes and in receptor-selective isolated tissue studies. Olanzapine had no agonist activity at any of the receptors examined. However, olanzapine was a potent antagonist of 5-HT-stimulated increases in IP3 in cell lines transfected with 5-HT2A or 5-HT2B receptors with IC50 values of 30-40 nM. Olanzapine weakly blocked 5-HT-induced formation of IP3 in cell lines transfected with 5-HT2c receptors, but in this cell line potently inhibited 5-HT-stimulated [35S]GTP gamma S binding with a Ki value of 15 nM. Olanzapine blocked dopamine-stimulated adenylyl cyclase in rat retina with modest potency (Ki = 69 nM), consistent with its relatively low affinity for dopamine D1 receptors. Olanzapine blocked agonist-induced activities at the muscarinic receptor subtypes M1, M2, M3, and M5 with Ki values of 70, 622, 126, and 82 nM, respectively. In studies using cell lines transfected with muscarinic M4 receptors, olanzapine and the atypical antipsychotic clozapine did not have agonist activities as determined with cAMP inhibition and stimulation assays, arachidonic acid release and [35S]GTP gamma S binding assays. However, olanzapine antagonized agonist-induced effects in muscarinic M4 cells with a Ki value of 350 nM. In isolated tissue studies, olanzapine potently blocked agonist-induced effects at alpha 1-adrenergic and histamine H1 receptors (KB = 9 and 19 nM, respectively). Thus, olanzapine was an antagonist at all receptors investigated and was a particularly potent antagonist at 5-HT2A, 5-HT2B, 5-HT2C, alpha 1-adrenergic and histamine H1 receptors. Olanzapine was a weaker antagonist at muscarinic and dopamine D1 receptors.

Integrity signals

Registry

Crossref · 10.1016/s0920-9964(98)00146-7

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.
DeLÉAN, A., Munson, P. J., & Rodbard, D. (1978) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1978.235.2.e97 · Cited by 2,384
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,352
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Gompel, P. V., Lesage, A. S., Loore, K. D., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P. M., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,061
Self-citation
Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum
Stoof, J. C., & Kebabian, J. W. (1981) · Nature · doi:10.1038/294366a0 · Cited by 920
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G. D., Tran, P., SATTERLEE, W. G., Sanger, T. M., & Hamilton, S. H. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 777
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes
Peralta, E. G., Ashkenazi, A., Winslow, J. W., Ramachandran, J., & Capon, D. J. (1988) · Nature · doi:10.1038/334434a0 · Cited by 658
The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task
Sawaguchi, T., & Goldman‐Rakic, P. S. (1994) · Journal of Neurophysiology · doi:10.1152/jn.1994.71.2.515 · Cited by 649

Show all 62 references

Sorted by citations

Items 101–200 of 205

2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery
Bender, A. M., Parr, L. C., Livingston, W. B., Lindsley, C., & Merryman, W. D. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01178 · Cited by 19
An investigation of the behavioral mechanisms of antipsychotic action using a drug–drug conditioning paradigm
Li, M., He, W., & Mead, A. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32832a8f66 · Cited by 22
Differential Effects of M1 and 5-Hydroxytryptamine1A Receptors on Atypical Antipsychotic Drug-Induced Dopamine Efflux in the Medial Prefrontal Cortex
Li, Z., Prus, A. J., Dai, J., & Meltzer, H. Y. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.155663 · Cited by 22
Treatment of glossodynia with olanzapine
Gick, C. L., Mirowski, G. W., Kennedy, J. S., & Bymaster, F. P. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.02.016 · Cited by 22
Self-citation
Quantitative determination of olanzapine in rat brain tissue by high-performance liquid chromatography with electrochemical detection
Bao, J., & Potts, B. D. (2001) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)00518-1 · Cited by 22
Comparative effects of olanzapine and ziprasidone on hypophagia induced by enhanced histamine neurotransmission in the rat
Davoodi, N., Kalinichev, M., & Clifton, P. G. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282f62c66 · Cited by 21
Atypical antipsychotic clozapine reversed deficit on prepulse inhibition of the acoustic startle reflex produced by microinjection of DOI into the inferior colliculus in rats
de Oliveira, R. P., Nagaishi, K. Y., & Silva, R. C. B. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.01.053 · Cited by 21
Low baseline serotonin-2A receptors predict clinical response to olanzapine in first-episode schizophrenia patients
Arranz, B., Rosel, P., San, L., Ramírez, N. D., Dueñas, R., Salavert, J., Centeno, M., & del Moral, E. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2006.12.015 · Cited by 21
Handbook of neurochemistry and molecular neurobiology, schizophrenia
Lajtha, Á., Javitt, D. C., & Kantrowitz, J. T. (2009) · Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) · doi:10.1007/978-0-387-30410-6 · Cited by 21
Olanzapine May Inhibit Colonic Motility Associated with the 5-HT Receptor and Myosin Light Chain Kinase
Zhang, J., Qiao, Y., Le, J., Sun, D., Guan, Y., & Li, Z. (2016) · Psychiatry Investigation · doi:10.4306/pi.2016.13.2.232 · Cited by 20
Cannabinoids for the Treatment of Schizophrenia? A Balanced Neurochemical Framework for Both Adverse and Therapeutic Effects of Cannabis Use
Coulston, C. M., Perdices, M., Henderson, A. F., & Malhi, G. S. (2010) · Schizophrenia Research and Treatment · doi:10.1155/2011/501726 · Cited by 18
Computational Investigation of Montelukast and Its Structural Derivatives for Binding Affinity to Dopaminergic and Serotonergic Receptors: Insights from a Comprehensive Molecular Simulation
Alotaiq, N., & Dermawan, D. (2025) · Pharmaceuticals · doi:10.3390/ph18040559 · Cited by 18
Échelles d’évaluation de l’effet anticholinergique des médicaments
Mebarki, S., & Trivalle, C. (2012) · NPG. Neurologie, psychiatrie, gériatrie/NPG · doi:10.1016/j.npg.2012.03.002 · Cited by 17
Is Neuronal Histamine Signaling Involved in Cancer Cachexia? Implications and Perspectives
Zwickl, H., Zwickl-Traxler, E., & Pecherstorfer, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01409 · Cited by 18
Olanzapine interaction with dipalmitoyl phosphatidylcholine (DPPC) and 1-palmitoyl-2-oleoyl phosphatidylserine (POPS) bilayer: A 13C and 31P solid-state NMR study
Song, C., & Nerdal, W. (2008) · Biophysical Chemistry · doi:10.1016/j.bpc.2008.01.002 · Cited by 17
Schizophrénie, diabète et antipsychotiques
Gury, C. (2004) · L Encéphale · doi:10.1016/s0013-7006(04)95452-8 · Cited by 16
A low TSH profile predicts olanzapine-induced weight gain and relief by adjunctive topiramate in healthy male volunteers
Evers, S. S., van Vliet, A., van Vugt, B., Scheurink, A. J. W., & van Dijk, G. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.12.024 · Cited by 15
Population pharmacokinetics of olanzapine in children
Maharaj, A. R., Wu, H., Zimmerman, K. O., Autmizguine, J., Kalra, R., Al-Uzri, A. Y., Sherwin, C. M. T., Goldstein, S. L., Watt, K., Erinjeri, J., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14414 · Cited by 15
pH-dependent interaction of psychotropic drug with glycerophospholipid monolayers studied by the Langmuir technique
Steinkopf, S., Simeunović, A., Bustad, H. J., Ngo, T. H., Sveaass, H., Gjerde, A. U., & Holmsen, H. (2010) · Biophysical Chemistry · doi:10.1016/j.bpc.2010.08.001 · Cited by 15
Concentration and time dependant behavior of chlorpromazine interaction with supported bilayer lipid membrane
Liu, X., Bai, H., Huang, W., Du, L., Yang, X., & Wang, E. (2005) · Electrochimica Acta · doi:10.1016/j.electacta.2005.07.034 · Cited by 15
Olanzapine: a 5-year perspective
Littrell, K. H., Petty, R. G., & Wolf, N. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.6.811 · Cited by 15
Atypical antipsychotic olanzapine reversed deficit on prepulse inhibition of the acoustic startle reflex produced by microinjection of dizocilpine (MK-801) into the inferior colliculus in rats
Zangrando, J., Carvalheira, R., Labbate, G. P., de Medeiros, P. S., Longo, B. M., Melo-Thomas, L., & da Silva, R. C. B. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.09.018 · Cited by 14
Cardiovascular effects of acute treatment with the antipsychotic drug olanzapine in rats
Leung, J. Y. T., Pang, C. C. Y., Procyshyn, R. M., & Barr, A. M. (2014) · Vascular Pharmacology · doi:10.1016/j.vph.2014.06.003 · Cited by 15
Practitioner Review: The effects of atypical antipsychotics and mood stabilisers in the treatment of depressive symptoms in paediatric bipolar disorder
Atkin, T., Núñez, N. A., & Gobbi, G. (2017) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12735 · Cited by 15
Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study
Kawazoe, H., Uozumi, R., Murakami, A., Yamashita, M., Kobayashi-Taguchi, K., Kusakabe, E., Yamasawa, H., Yakushijin, Y., Nakamura, T., & Kamei, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-34618-x · Cited by 13
Effect of acute and chronic olanzapine treatment on phencyclidine-induced behavioral sensitization in rats with neonatal dopamine loss
Moy, S. S., Fernandes, A., Ying, Q., Rotella, D. J., Kostrewa, R. M., & Breese, G. R. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.02.013 · Cited by 14
Olanzapine and sibutramine have opposing effects on the motivation for palatable food
van der Zwaal, E. M., Janhunen, S. K., Luijendijk, M. C. M., Baclesanu, R., Vanderschuren, L. J. M. J., Adan, R. A. H., & la Fleur, S. E. (2012) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283512ca1 · Cited by 13
Heart rate variability during sleep in patients with schizophrenia treated with olanzapine
Mann, K., Rossbach, W., ller, M. J. M., Muller-Siecheneder, F., Ru, H., & Dittmann, R. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200411000-00002 · Cited by 13
The Comparative Peripheral Anticholinergic-Like Adverse Event Profiles of Olanzapine and Risperidone
Kennedy, J. S., Bymaster, F. P., Basson, B. R., Gilmore, J. A., & Trân, P. V. (2000) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v02n0403 · Cited by 13
Self-citation
Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent
Tollefson, G. D., & Taylor, C. C. (2000) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2000.tb00155.x · Cited by 12
Serum Metabolic Profile in Schizophrenia Patients With Antipsychotic-Induced Constipation and Its relationship With Gut Microbiome
Amdanee, N., Shao, M., Hu, X., Fang, X., Zhou, C., Chen, J., Chattun, M. R., Wen, L., Pan, X., Zhang, X., et al. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac202 · Cited by 12
Dopaminergic and norepinephrinergic modulation of endogenous event-related potentials: A systematic review and meta-analysis
Warren, C. V., Kroll, C., & Kopp, B. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105221 · Cited by 11
Atypical antipsychotic olanzapine inhibits voltage-dependent K+ channels in coronary arterial smooth muscle cells
Kang, M., An, J. R., Seo, M. S., Jung, H. S., Heo, R., Park, H., Song, G., Jung, W., Choi, I., & Park, W. S. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00299-z · Cited by 11
Effects of olanzapine on aggressiveness in heroin dependent patients
Gerra, G., Petta, G. D., d’Amore, A., Iannotta, P., Bardicchia, F., Falorni, F., Coacci, A., Strepparola, G., Campione, G., Lucchini, A., et al. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.04.023 · Cited by 11
The Management of Nausea and Vomiting Not Related to Anticancer Therapy in Patients with Cancer
Hardy, J. R., & Davis, M. P. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00813-0 · Cited by 12
Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a DAT scan
Rizos, E. N., Chatziioannou, S. N., Douzenis, A., Siafakas, N., Katsantoni, E. Z., Nikolaidou, P., Papathanasiou, M., & Lykouras, L. P. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.08.002 · Cited by 10
The atypical antipsychotic olanzapine disturbs depotentiation by modulating mAChRs and impairs reversal learning
Song, W. S., Cha, J. H., Yoon, S. H., Cho, Y. S., Park, K.-Y., & Kim, M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.11.012 · Cited by 10
Antiemetic Efficacy of Adding Olanzapine 5 mg to Aprepitant, Palonosetron and Dexamethasone-Sparing After Day Two for Cancer Patients Receiving Anthracycline and Cyclophosphamide
Suehiro, M., Kojima, Y., Takahashi, M., Ito, Y., Keira, T., Ikegawa, K., Minatogawa, H., Tsugawa, K., & Tanaka, T. (2021) · Cancer Management and Research · doi:10.2147/cmar.s280995 · Cited by 8
Risk, Self Selection and Advice: Banks Versus Venture CapitalistsPreprint
Dietz, M. D. (2002) · SSRN Electronic Journal · doi:10.2139/ssrn.302080 · Cited by 9
A Novel Gliotransmitter, L-β-Aminoisobutyric Acid, Contributes to Pathophysiology of Clinical Efficacies and Adverse Reactions of Clozapine
Fukuyama, K., Motomura, E., & Okada, M. (2023) · Biomolecules · doi:10.3390/biom13091288 · Cited by 8
A Novel Synthetic Interfering Peptide Tat-3L4F Attenuates Olanzapine-Induced Weight Gain Through Disrupting Crosstalk Between Serotonin Receptor 2C and Protein Phosphatase and Tensin Homolog in Rats
Wang, Y., Wang, D., Chen, Y., Fang, X., Yu, L., & Zhang, C. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa001 · Cited by 8
The SWITCH study: rationale and design of the trial
Heres, S., Cirjaliu, D., Dehelean, L., Matei, V. P., Podea, D. M., Sima, D., Stecher, L., & Leucht, S. (2015) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-015-0624-y · Cited by 7
LLY-2707, A Novel Nonsteroidal Glucocorticoid Antagonist That Reduces Atypical Antipsychotic–Associated Weight Gain in Rats
Sindelar, D. K., Carson, M. W., Morin, M., Shaw, J., Barr, R. J., Need, A. B., Alexander-Chacko, J. T., Coghlan, M. J., & Gehlert, D. R. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.205864 · Cited by 7
Olanzapine Causes a Leptin-Dependent Increase in Acetylcholine Release in Mouse Prefrontal Cortex
Wathen, A. B., West, E. S., Lydic, R., & Baghdoyan, H. A. (2012) · SLEEP · doi:10.5665/sleep.1686 · Cited by 7
Synthesis of N-(3-arylprop-2-ynyl)substituted olanzapine derivatives as potential inhibitors of PDE4B
Babu, P. V., Gorja, D. R., Meda, C. L. T., Deora, G. S., Kolli, S. K., Parsa, K. V. L., Mukkanti, K., & Pal, M. (2014) · Tetrahedron Letters · doi:10.1016/j.tetlet.2014.04.009 · Cited by 7
Persistent Amnesia as a Sequel of Olanzapine-Induced Neuroleptic Malignant Syndrome
Mendhekar, D. N., & Duggal, H. S. (2006) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.18.4.552 · Cited by 7
Gi/Go protein‐dependent presynaptic mechanisms are involved in clozapine‐induced down‐regulation of tyrosine hydroxylase in PC12 cells
Tejedor‐Real, P., Vogel, R., Mallet, J. J., & Biguet, N. F. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20585 · Cited by 7
Serotonin Receptors as Targets of Antipsychotic Medications
Abi‐Dargham, A., & Krystal, J. H. (2000) · Handbooks of pharmacology and toxicology · doi:10.1201/9781420041774.ch6 · Cited by 7
Evaluation of atypical antipsychotics associated rhabdomyolysis using the FDA adverse event reporting system database
Yi, Y., Jiang, J., & Jin, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-95700-9 · Cited by 6
The effects in rats of lisdexamfetamine in combination with olanzapine on mesocorticolimbic dopamine efflux, striatal dopamine D2 receptor occupancy and stimulus generalization to a d-amphetamine cue
Hutson, P. H., Rowley, H. L., Gosden, J., Kulkarni, R. S., Slater, N., Love, P. L., Wang, Y., & Heal, D. J. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.09.014 · Cited by 6
Effect of 5-HT2A/2B/2C receptor agonists and antagonists on sleep and waking in laboratory animals and humans
Kitka, T., & Bagdy, G. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8561-3_15 · Cited by 6
Fos expression induced by olanzapine and risperidone in the central extended amygdala
Pinna, A., Costa, G., Contu, L., & Morelli, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172764 · Cited by 6
Chemogenomics
Kubinyi, H. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00113-9 · Cited by 6
Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders
Ibragimov, K., Keane, G., Glaría, C. C., Cheng, J. J., & Llosa, A. E. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013425.pub2 · Cited by 4
Agitation: Neurobiology and current management guidelines
Miller, C. W. T., Rullo, M., Remmen, S. V., & Mahmood, S. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.11.068 · Cited by 5
OLANZAPINE COMBINED WITH STANDARD ANTIEMETIC REGIMENS FOR PREVENTION OF CHEMOTHERAPY THERAPY-INDUCED NAUSEA AND VOMITING: A SINGLE-CENTER EXPERIENCE FROM SOUTH INDIA
James, E., Drisya, P., & Jose, W. M. (2017) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2017.v10i11.18864 · Cited by 5
Olanzapine dose for people with schizophrenia
Latifeh, Y., Mohsen, M., Mohamad, S., & Nassif, T. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013266 · Cited by 5
Suivi thérapeutique pharmacologique de l’olanzapine
Djerada, Z., Brousse, G., Niel, P., Llorca, P., Eschalier, A., Bentué‐Ferrer, D., & Libert, F. (2015) · Therapies · doi:10.2515/therapie/2015040 · Cited by 5
Tako–Tsubo Syndrome in a psychiatric woman with bipolar disorder
Gennaro, L. D., Tommasi, E. D., Ramunni, G., Boscia, F., Biase, M. D., & Brunetti, N. D. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.09.053 · Cited by 5
The Emerging Role of Olanzapine in Bipolar Disorders
Ketter, T. A., Wang, P. W., Janenawasin, S., Becker, O. V., & Wang, A. (2002) · Psychiatric Annals · doi:10.3928/0048-5713-20021201-10 · Cited by 5
Haloperidol versus olanzapine for people with schizophrenia
Ibragimov, K., Keane, G., Glaría, C. C., Cheng, J., & Llosa, A. E. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013425 · Cited by 4
Pharmacotherapy Options for the Management of Cluster Headache
Pomeroy, J. L., & Marmura, M. J. (2013) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s10251 · Cited by 4
Campaign Rhetoric: A Model of ReputationPreprint
Aragonès, E., & Postlewaite, A. (2001) · SSRN Electronic Journal · doi:10.2139/ssrn.273410 · Cited by 4
Neuroprotective Effects of Olanzapine in N -Methyl- d -Aspartate-Induced Retinal Injury
Önder, H. İ., Aktan, G., Yüksel, H., Avcıoglu, S., Yıldırım, Ü., Kaya, M., Tunç, M., & Gökçe, F. M. (2012) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2012.0075 · Cited by 3
Olanzapine-associated hypothermia in an adolescent anorexic girl
Docx, M. K. F., Simons, A., Ramet, J., Mertens, L., & Govaert, P. P. (2012) · Open Journal of Clinical Diagnostics · doi:10.4236/ojcd.2012.24017 · Cited by 3
The effect of olanzapine on lipid profiles in humans: a time and dose response meta-analysis of randomized controlled trials
Zhou, F., Jamilian, P., Safargar, M., Prabahar, K., & Liu, S. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05476-z · Cited by 2
Nausea and vomiting during post-transplantation cyclophosphamide administration
Nakashima, T., Inamoto, Y., Ito, A., Tanaka, T., Kim, S., Fukuda, T., Makino, Y., Hashimoto, H., & Yamaguchi, M. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02927-5 · Cited by 2
["DISCOVERING THE MOLECULAR AND CELLULAR MECHANISMS UNDERLYING FENFLURAMINE-INDUCED CARDIOPULMONARY SIDE EFFECTS"]
Setola, V. (2005) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 2
Does the Heat Stress Affect the Neurons Development in Some Central Nervous System Regions of Albino Rat Newborns?
Ahmed, O. M., Ahmed, R. G., Nada, M. M. S., & ., M. B. (2007) · Asian Journal of Animal and Veterinary Advances · doi:10.3923/ajava.2007.86.103 · Cited by 2
Effects of clozapine, olanzapine and haloperidol on ethanol-induced ascorbic acid release in mouse striatum
Hou, Y., Yang, J., Wu, C. F., & Huang, M. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.10.009 · Cited by 2
Molecular mechanisms of olanzapine against agitation in schizophrenia and bipolar disorder based on network pharmacology and molecular docking
Shi, X., Chen, X., Ma, X., Li, R., Yang, J., Chen, C., Chen, L., Chen, G., Li, C., & Zhuo, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-24139-9 · Cited by 1
The Serotonin 2B (5‐ HT2B ) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression
Le, G. H., Wong, S., Johnson, D. E., Orsini, D. K., Zheng, Y. J., Teopiz, K. M., Dri, C. E., Rosenblat, J. D., & McIntyre, R. S. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70344 · Cited by 1
Olanzapine antagonizes the acquisition and expression of morphine-induced conditioned place preference in male and female mice
Hafez-Amini, P., Shams, J., Shabahng-Saber-Tehrani, A., Haeri-Rohani, A., Parivar, K., Babapour, V., & Sahraei, H. (2006) · Cited by 1
Attenuated Weight Gain with the Novel Analog of Olanzapine Linked to Sarcosinyl Moiety (PGW5) Compared to Olanzapine
Taler, M., Vered, I., Globus, R., Shbiro, L., Weizman, A., Weller, A., & Gil‐Ad, I. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0679-2 · Cited by 1
The antagonist SPECT tracer 123I-iododexetimide binds preferentially to the muscarinic M1 receptor in-vivo, but is it also a potential tool to assess the occupancy of muscarinic M1 receptors by agonists?
Bakker, G., Chekrouni, N., Vingerhoets, W. A. M., van Wieringen, J., de Bruin, K. M., Eersels, J. L. H., de Jong, J., Chahid, Y., Bloemen, O., van Amelsvoort, T., et al. (2016) · Receptors & Clinical Investigation · doi:10.14800/rci.1163 · Cited by 1
Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders
Zang, Y., Wan, Z., Jia, F., Yang, Q. J., Liu, C., Wang, Q., Liu, S., Dong, F., Li, A., de León, J., et al. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2380472 · Cited by 1
Promising novel drug delivery approaches in the development of therapeutics for schizophrenia disease management
Shareena, G., & Kumar, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13474-6.00026-3 · Cited by 1
Olanzapine-induced paraesthesia: A less reported side effect
Tyagi, S., Verma, V., Saini, V. K., & Kaur, H. (2025) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_637_24 · Cited by 1
An Empirical Analysis of Technological Convergence Process and Rjvs in Europe at the Firm LevelPreprint
Bussoli, P. (2000) · SSRN Electronic Journal · doi:10.2139/ssrn.229251 · Cited by 1
Sleep in mental and behavioural disorders
Lindberg, N. (2003) · Työväentutkimus Vuosikirja · Cited by 1
Cholinergic Mechanisms in Schizophrenia
Raedler, T. J., & Freedman, R. (2009) · Springer eBooks · doi:10.1007/978-0-387-30410-6_2 · Cited by 1
Mechanisms for the development of olanzapine-induced weight gain: roles of ghrelin signalling, thermogenesis, and inflammation
Zhang, Q. (2014) · Research Online (University of Wollongong)
Antipsychotica geïnduceerd overgewicht en insulineresistentie
Evers, S. S., & Scheurink, A. J. W. (2012) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-012-0012-4
Olanzapine-induced weight gain
van der Zwaal, E. M., Luijendijk, M. C. M., Adan, R. A. H., & la Fleur, S. E. (2008) · Appetite · doi:10.1016/j.appet.2008.04.248
The Effects of Atypical Antipsychotics on Implicit Reward Learning in Schizophrenia
Bradford, L. (2015) · QSpace (Queen's University Library)
Loxapin — ein neues Antipsychotikum?
Walter, U., Wenzel‐Seifert, K., & Haen, E. (2016) · NeuroTransmitter · doi:10.1007/s15016-016-5448-0
Olanzapine - Focus on the Cardiometabolic Side Effects
Mitrović, M., Nikolic, T. R., Turnic, M., & Djurić, D. (2018) · Serbian Journal of Experimental and Clinical Research · doi:10.1515/sjecr-2017-0054
Influencia del sexo en el tratamiento con olanzapina: una revisión sistemática
Alberich, S., Martínez‐Cengotitabengoa, M., González–Ortega, I., Fernández-Sevillano, J., Usall, J., & González-Pinto, A. M. (2019) · Psiquiatría Biológica · doi:10.1016/j.psiq.2019.06.001
Effects of Olanzapine on the Pacemaker Potentials of Interstitial Cells of Cajal in Murine Small Intestine
Kim, B. J. (2019) · JoLS Journal of Life Sciences · doi:10.5352/jls.2019.29.9.1010
Olanzapine in the Treatment of Psychosis
Laux, G. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_453-1
Olanzapine in the Treatment of Psychosis
Laux, G. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_453
A case of new-onset mania in older adulthood related to cannabidiol and low-dose prescription stimulant use
Alilonu, N. A., Smolen, K. A., Kolaj, S., & Reed, J. (2025) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2025.100300
Mirtazapine and olanzapine for cancer-related psychological distress in advanced oral cancer: efficacy and safety prospective study
Singhal, Y., Pingoliya, S. K., Pavan Gaurav, R., & Saji, S. (2025) · BMJ Supportive & Palliative Care · doi:10.1136/spcare-2025-005706
CHARACTERIZATION OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF THE ATYPICAL ANTIPSYCHOTIC AMISULPRIDE IN C57BL/6 MICE
Donahue, T. J. (2014) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/sy1b-7s46
A structural overview of G-protein-coupled receptors in neurological disorders
Gupta, O. D., Chakraborty, I., & Pal, K. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01712-6
Significant Anxiolytic Effect and Enhanced Recovery Benefits of Perioperative Low-Dose Olanzapine in Patients with Anxiety Undergoing THA
Jiang, B., Fan, J., Lai, Y., Cai, Y., Ding, Z., Luo, Z., & Zhou, Z. (2026) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.25.01236
Practical prescribing in cancer cachexia
Monnery, D., Collins, J., & Droney, J. (2026) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000814
Potential adverse effects of antipsychotics during pregnancy: A narrative review with a focus on metabolic alterations
Ramírez‐Herrera, O., D’Espessailles, A., Burrone, M. S., & Santander, N. G. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118266
BindingDB Entry 50038418: Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs.
BindingDB (2012) · UC San Diego · doi:10.7270/q2mp544f
BindingDB Entry 5252: Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium.
BindingDB (2012) · UC San Diego · doi:10.7270/q2wm1bzz

Authors: Bymaster, F.
Affiliations: Eli Lilly (United States) (US)
Corresponding author: Bymaster, F
Venue: Schizophrenia Research
Publisher: Elsevier BV
Published: 1999-05-04
Volume: 37
Issue: 1
Pages: 107-122
ISSN: 0920-9964 (ISSN-L)
DOI: 10.1016/s0920-9964(98)00146-7
OpenAlex: W2113107587
Cited by: 200
References: 62
Citations by year: 2026: 6 · 2025: 6 · 2024: 6 · 2023: 4 · 2022: 2 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 4 · 2017: 5 · 2016: 8 · 2015: 10 · 2014: 5 · 2013: 5 · 2012: 10
FWCI: 3.56
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Schizophrenia Research (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords: olanzapine, atypical antipsychotics
MeSH terms: Olanzapine, Adenylyl Cyclases, Animals, Benzodiazepines, Cells, Cultured, Cricetinae, Kinetics, Pirenzepine, Receptors, Adrenergic, alpha, Receptors, Histamine H1, Receptors, Muscarinic, Receptors, Serotonin, Retina, Receptors, Dopamine D1, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1-adrenergic receptors in vitro

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks